

Figure 3. Effect of Smad2 inhibition on cardiac differentiation in ES cells. A, α-MHC–EGFP ES cells were treated with the various concentrations of SB-431542 (SB) for the indicated periods of time. Cardiac differentiation was monitored by the appearance of EGFP-expressing cells. B, The proportions of EGFP-positive cardiac myocytes were examined by flow cytometric analysis. C, The effect of SB-431542 on Smad2 phosphorylation was assessed by immunoblot analysis in naïve ES cells. D, Naïve ES cells were treated with or without SB-431542 as indicated, and the total number of viable cells was counted with trypan blue exclusion at days 8 and 12. E, Nontransfected naïve ES cells were treated with or without SB-431542 or DMSO as indicated, and the expression of α-MHC, cTnI, and ANP was analyzed. The results are plotted as percentages of the control value. F, Expression of sarcomeric myosin and α-actinin was examined by immunoblot analysis. *$P<0.05$ vs respective DMSO control.

cardiomyogenesis was markedly augmented in a dose-dependent manner. At 10 μmol/L SB-431542, the proportion of cardiac myocytes reached 13.2%, a more than 3-fold increase over the control (Figure 3B). A vehicle control, DMSO, did not influence the proportion of cardiac myocytes (Figure 3B). Inhibition of the late activation of Smad2 did not alter general growth properties, as treatment of cells with SB-431542 in the late phase alone did not alter the total viable cell number of the cultures (Figure 3D). These results indicated that SB-431542 treatment in the late phase alone results in a 3-fold increase in the yield of cardiac myocytes from the same scale of culture. These EGFP-positive cells were cardiac myocytes, as stained positively with antibody against sarcomeric α-actinin or cTnI and showing a myofibrillar structure (data not shown).

Analysis of cardiac gene expression in nontransfected naïve ES cells revealed that expression of cardiac-specific genes such as α-MHC, cTnI, and ANP was almost completely inhibited by SB-431542 when used in the early phase, whereas the expression of these genes showed an ≈3-fold increase when treated only in the late phase (Figure 3E). Furthermore, protein expression of sarcomeric myosin and α-actinin exhibited the results consistent with the gene expression analysis (Figure 3F). These results clearly demonstrated that Smad2 activation in the early phase is essential for cardiomyogenesis, whereas the late activation of Smad2 negatively regulates cardiomyogenesis of ES cells.

Treatment With SB-431542 in the Early Phase Inhibits Mesodermal and Endodermal Induction but Augments Neuroectodermal Differentiation

As treatment of cells with SB-431542 in the early phase inhibited cardiac differentiation, the effect of SB-431542 on expression of markers for 3 germ layers was analyzed (Figure 4A through 4D). Mesodermal markers such as Brachyury and Flk1 and endodermal markers such as Mixl1, Foxa2, and α-fetoprotein were downregulated by SB-431542 (Figure 4A and 4B), whereas the expression of neuroectodermal markers such as Pax6, neurogenic differentiation 1 (Neurod1), and neurogenin 2 (Neurog2) was upregulated (Figure 4C and 4D). Immunostaining with sarcomeric α-actinin and βIII-tubulin (Figure 4E), and counting the percentages of EBs positively stained with βIII-tubulin or containing the beating area (Figure 4F), also revealed that SB-431542 treatment in the

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009



Figure 4. Inhibited mesodermal and endodermal formation and augmented neuroectodermal formation by treatment with SB-431542 in the early phase. Naïve ES cells were treated with or without SB-431542 and harvested at the indicated time points. A and B, The expression of mesodermal markers such as Brachyury and Flk1 was analyzed by RT-PCR. *$P<0.05$ vs control at day 3, #$P<0.05$ vs control at day 5. C and D, The expression of neuronal markers such as Pax6, Neurod1, and Neurog2 was analyzed. *$P<0.05$ vs control at day 5, #$P<0.05$ vs control at day 12. E, α-MHC–EGFP cells were treated with or without SB-431542 and immunostained with antibody against βIII-tubulin or sarcomeric α-actinin at day 12. F, The proportions of EBs positively stained with βIII-tubulin or containing the beating area were counted. *$P<0.05$ vs control.

early phase resulted in impaired cardiac differentiation and enhanced neuronal differentiation. These results indicated that, in the early phase, activation of Smad2 is indispensable for mesodermal and endodermal differentiation, and once this pathway is inhibited, neuroectodermal differentiation is enhanced.

Tbx5 Is Markedly Upregulated by SB-431542 Treatment in the Late Phase

The effect of SB-431542 treatment in the late phase on the expression of cardiac transcription factors such as Nkx2.5, GATA4, Tbx5, Tbx20, Mef2C, myocardin, and isl1 was examined at day 8 (Figure 5A). Among these factors, GATA4, Tbx5, Tbx20, and Mef2C were significantly upregulated by treatment with SB-431542. The upregulation of Tbx5 was remarkable and reached a level ≈6-fold that of the untreated control, implying a role of increased Tbx5 expression in augmented cardiomyogenesis by Smad2 inhibition in the late phase.

Endogenous TGF-β and Activin Negatively Regulate Cardiomyogenesis in the Late Phase

To determine the responsible endogenous ligands for the inhibition of cardiomyogenesis through Smad2 activation in the late phase, effects of neutralizing antibodies against TGF-β and activin on cardiomyogenesis were examined (Figure 5B). Although treatment with either anti-TGF-β or anti-activin antibody in the late phase resulted in a significant increase in cardiomyogenesis, anti–TGF-β neutralizing antibody was clearly more potent than anti-activin antibody, exhibiting a 2-fold increase in cardiomyogenesis (Figure 5B). To further reveal the role of endogenous TGF-β and Smad2, the effect of a soluble TGF-β type II receptor (sTGF-β IIR)[9] and a dominant negative mutant of Smad2 (Smad2 DN)[8] was analyzed (Figure 5C through 5F). Cells were infected with an adenovirus expressing sTGF-β IIR or β-galactosidase at day 0 or 5 and analyzed for cardiomyogenesis. Inhibition of TGF-β action by sTGF-β IIR indeed attenuated Smad2 phosphorylation in the late phase (Figure 5C) and augmented cardiomyogenesis, as assessed by the expression of cardiac genes (Figure 5D). Even when the cells were infected at day 0 with an adenovirus expressing sTGF-β IIR, cardiomyogenesis was increased to the similar extent to the cells infected at day 5 (Figure 5D). Furthermore, infection of cells with an adenovirus expressing Smad2 DN at day 5, which indeed inhibited Smad2 activation in the late phase (Figure 5E), enhanced cardiomyogenesis (Figure 5F). Thus, endogenous

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009



Figure 5. Effect of SB-431542 on cardiac transcription factor expression, effects of neutralizing antibodies against TGF-β and activin, and adenovirus-mediated expression of sTGF-β IIR and Smad2 DN. A, Naïve ES cells were treated with or without SB-435142 after day 5. The expression of Nkx2.5, GATA4, Tbx5, Tbx20, Mef2C, myocardin, and isl1 was analyzed at day 8. B, α-MHC–EGFP ES cells were treated with or without a neutralizing antibody against TGF-β or activin or isotype-matched control antibody after day 5, and the proportion of EGFP-expressing cardiac myocytes was analyzed at day 12. *$P<0.05$ vs control, #$P<0.05$ vs anti-activin antibody. C and D, Naïve ES cells were infected with an adenovirus expressing sTGF-β IIR or LacZ at day 0 or day 5 and cultured until day 12. Expression of sTGF-β IIR and phosphorylation of Smad2 (C), and expression of α-MHC and cTnI (D) was analyzed. *$P<0.05$ vs control. E and F, Naïve ES cells were infected with an adenovirus expressing Smad2 DN or LacZ at day 5 and cultured for 7 more days. Phosphorylation of Smad2 (E) and expression of α-MHC and cTnI (F) were analyzed. *$P<0.05$ vs control.

TGF-β and activin act as negative regulators of cardiomyogenesis in the late phase, and TGF-β–mediated Smad2 activation plays a major role in the negative control of cardiomyogenesis.

TGF-β–Smad2 Signaling Negatively Modulates Both Proliferation and Differentiation of Cardiac Myocytes

As TGF-β–Smad2 signaling is known to be a multifunctional factor that regulates proliferation as well as differentiation in various cell types, we sought to determine whether the inhibition of TGF-β–Smad2 signaling enhanced cardiomyogenesis by increasing proliferation of cardiac myocytes or directing the cells to differentiate into cardiac myocytes. To analyze cardiac myocytes and nonmyocytes individually, we sorted α-MHC–EGFP ES cells as EGFP-positive cardiac myocytes and EGFP-negative nonmyocytes at day 8. The proliferative activities were assessed by BrdUrd labeling and phospho–histone H3 staining. EGFP-positive cardiac myocytes retained greater replicative potential in ES cells expressing sTGF-β IIR or treated with SB-431542 than control cells, as the percentages of BrdUrd-incorporated and phospho–histone H3–positive cells were significantly higher in the cells expressing sTGF-β IIR or treated with SB-431542 (Figure 6A). The proliferation of EGFP-negative nonmyocytes was not altered by these interventions (Figure 6A). These results indicated that endogenous TGF-β–Smad2 signaling negatively modulates the proliferation of differentiated cardiac myocytes. As diverse signaling mediators have been implicated in the antiproliferative effect of TGF-β–Smad2 signaling including N-myc, c-myc, cdc25A, and cyclin-dependent kinase inhibitors,[2] expression of these genes in cardiac myocytes and nonmyocytes was examined. sTGF-β IIR expression or SB-431542 treatment in the late phase upregulated N-myc, c-myc, cyclin A2, and cdc25A specifically in cardiac myocytes, but not in nonmyocytes (Figure 6B). Furthermore, downregulated expression of $p57^{KIP2}$, but not other cyclin-dependent kinase inhibitors such as $p15^{INK4B}$, $p21^{WAF1/CIP1}$, and $p27^{KIP1}$, was observed specifically in cardiac myocytes (Figure 6B). In nonmyocytes, expression of $p21^{WAF1/CIP1}$ was suppressed by sTGF-β IIR expression or SB-431542 treatment (Figure 6B).

To examine the role of TGF-β–Smad2 signaling in the differentiation process, EGFP-negative nonmyocytes were sorted at day 8 from ES cell culture with or without sTGF-β IIR expression (Figure 7A) or SB-431542 treatment (Figure

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009



Figure 6. Inhibition of TGF-β–Smad2 signaling in the late phase enhances proliferation of cardiac myocytes. α-MHC–EGFP ES cells were infected with an adenovirus expressing sTGF-β IIR or LacZ at day 5, or treated with or without SB-431542 after day 5. Cells were labeled with BrdUrd at day 8 and then sorted as EGFP-positive cardiac myocytes and EGFP-negative nonmyocytes. A, Sorted cells were stained for BrdUrd and phospho-histone H3, and the proportion of BrdUrd-positive or phospho–histone H3–positive cells was calculated among EGFP-positive cardiac myocytes and EGFP-negative nonmyocytes. #$P<0.05$ vs LacZ, *$P<0.05$ vs control. B, Real-time kinetic PCR was performed with the indicated specific primers. The results are expressed relative to the level of β-tubulin and plotted as percentages of the control value. #$P<0.05$ vs LacZ, *$P<0.05$ vs control.

7B through 7D) and cultured for 7 more days. In the case of SB-431542 treatment, cells were treated as indicated in Figure 7B: control; not treated, control to SB; treated only after sorting at day 8, SB; treated from day 5 to day 15, SB-431542 to (−); treated only from day 5 to day 8. Cardiomyogenesis was monitored by the expression of cardiac genes (Figure 7A and 7C), and the proportion of EGFP-positive cardiac myocytes (Figure 7D). Although the differentiation of EGFP-negative nonmyocytes into EGFP-positive cardiac myocytes was observed in control cells, more EGFP-positive cells were apparent in the cells expressing sTGF-β IIR or treated with SB-451542. Expression of cardiac genes α-MHC and cTnI was significantly enhanced by sTGF-β IIR expression (Figure 7A). Treatment with SB-451542 enhanced not only the expression of cardiac genes (Figure 7C) but also the proportion of cardiac myocyte–



Figure 7. Inhibition of TGF-β–Smad2 signaling enhances the differentiation of EGFP-negative nonmyocytes into EGFP-positive cardiac myocytes. A, α-MHC–EGFP ES cells were infected with an adenovirus expressing sTGF-βIIR or LacZ at day 5. EGFP-negative nonmyocytes were sorted at day 8 and then cultured on gelatin-coated dishes for 7 more days. The expression of α-MHC and cTnI was examined. #$P<0.05$ vs LacZ. B, α-MHC–EGFP ES cells were treated with or without SB-431542. EGFP-negative nonmyocytes sorted at day 8 were cultured with or without SB-431542 for 7 more days as indicated. C, The expression of α-MHC and cTnI was examined. *$P<0.05$ vs control. D, The proportion of EGFP-positive cardiac myocytes was analyzed at day 15. *$P<0.05$ vs control.

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

differentiated cells (Figure 7D), although treatment after cell sorting was critical for SB-431542 to augment cardiomyogenesis. These results suggested that inhibition of TGF-β–Smad2 signaling in the late phase resulted in not only augmented proliferation of cell that already differentiated into cardiac myocytes but also enhancement in cardiac myocyte differentiation.

Discussion

In this study, we found that Smad2 was activated bimodally in the early and late stages of ES cell differentiation, and gene expression of Smad2-activating ligands suggested that Smad2 activation in the undifferentiated and early phase was mediated by Nodal/Cripto. The roles of these components in early mammalian embryogenesis have been studied with genetic modifications in mice. Null mutants of Smad2 or activin receptor IIB result in a malformed primitive streak and failure of mesoderm to form.[12,13] Mice deficient in both Smad2 and Smad3 display a similar but more severe developmental phenotype than Smad2-null mutants, with a complete failure of gastrulation.[14] Our study showed that the early activation of Smad2 in ES cell differentiation was indispensable for mesodermal and endodermal induction, and its inhibition led to enhanced neuroectodermal induction. By using Cripto-deficient ES cells, Cripto is shown to be essential for cardiogenesis especially in the initial few days of ES cell differentiation.[15] A blockade of Nodal signaling by antagonists such as Lefty and Cerberus-short leads to extensive neuroectoderm development,[16] whereas Nodal gain-of-function experiments result in inhibition of neuroectoderm development.[17] Thus, our results with others indicated that Nodal/Cripto-dependent Smad2 activation is required for endodermal and mesodermal induction, and once this pathway is inhibited, neuroectodermal induction is augmented, supporting the neuroectoderm default model.[17]

Once inactivated at day 5, Smad2 was activated again at day 8, which was evident until day 12. During this period, TGF-βs and activin were induced to be expressed, suggesting that Smad2 activation in the late phase was stimulated by TGF-βs and activin. Our results with the inhibition of Smad2 activation in this late phase indicated that the late-phase activation is inhibitory to cardiomyogenesis of ES cells. Furthermore, with the neutralizing antibodies against TGF-β and activin, it was shown that both ligands are inhibitory to cardiomyogenesis, although TGF-β clearly plays a major role in suppressing cardiomyogenesis in the late phase. This was also demonstrated by the experiments with an adenovirus expressing sTGF-β IIR, in which blockade of TGF-β action resulted in enhanced cardiomyogenesis to a similar extent as anti–TGF-β neutralizing antibody. Enhanced cardiomyogenesis by the expression of sTGF-β IIR was observed even when cells were infected at day 0, suggesting TGF-β plays a major role in cardiomyogenesis in the late phase. In heart development, TGF-β has been shown to be critically involved in the formation of atrioventricular valvuloseptal and endocardial cushion tissues through a mechanism of epithelial–mesenchymal transition,[18] whereas less is known about the functions of TGF-β in cardiac myocyte differentiation. Furthermore, infection of cells with an adenovirus expressing Smad2 DN at day 5, which indeed inhibited Smad2 activation in the late phase, enhanced cardiomyogenesis. Our results demonstrated that Smad2 activation by endogenous TGF-β and activin in the late phase suppresses cardiac differentiation. This seems in conflict with previous reports indicating that the priming of undifferentiated ES cells with TGF-β enhances mesodermal and cardiac differentiation[19] and treatment with TGF-β2 augments cardiac differentiation of ES cells.[20] However, as the functional signaling pathways including the receptors for TGF-β exist in the initial phase of ES cell differentiation,[19,21] and our results indicated that Smad2 activation in the initial phase was indispensable for mesodermal induction, the effect of exogenous TGF-β in these studies might be through enhancing the induction of mesodermal lineages. Furthermore, TGF-β is secreted by extraembryonic tissues and also is expressed in early embryos at the stage of blastocysts in vivo.[22] As the interaction between the extraembryonic cell types and the primitive ectoderm, from which ES cells are derived, plays an integral role in mammalian embryonic development,[23] TGF-β from the extraembryonic tissues might be involved in mesodermal induction in vivo. However, as mouse ES cells are shown to irreversibly commit to an epiblast lineage and rarely spontaneously differentiate into trophectoderm and primitive endoderm derivatives,[23,24] autocrine Nodal and Cripto play an essential role in mesodermal induction in in vitro ES cell differentiation.

Tbx5 expression was markedly upregulated by SB-431542 treatment in the late phase. Tbx5 is a member of T-box gene family, whose mutations are responsible for human Holt–Oram syndrome, a disease involving a congenital heart malformation.[25] Tbx5 is shown to be expressed in cardiac crescent of murine embryos and regulates several cardiac genes such as ANP and connexin 40.[25] Although loss of Tbx5 alone does not prevent cardiac differentiation, overexpression of Tbx5 in P19Cl6 cells accelerates cardiac differentiation but is not sufficient to promote the commitment to cardiac lineage in the absence of the inducing agent DMSO.[25] Furthermore, a recent study revealed that Tbx5 regulates the embryonic proliferation of cardiac myocytes,[26] whereas the effect of Tbx5 on cardiac cell growth might be phase specific.[25,27] Thus, augmented expression of Tbx5 could be involved in the enhanced cardiomyogenesis induced by Smad2 inhibition, although further studies are needed to elucidate the functional relationship between Tbx5 expression and enhanced cardiomyogenesis.

TGF-β superfamily is known to regulate a plethora of biological responses such as cell growth, differentiation, and matrix production, and the effects of TGF-β depend on the type and status of the cells, sometimes producing opposing effects such as enhancing or suppressing cellular growth.[3] Several growth factors such as fibroblast growth factors, neuregulin, and insulin-like growth factor I have been shown to trigger the proliferation of myocardial cells.[28,29] However, less is known about the endogenous negative regulators of cardiac cell proliferation. By analyzing cardiac myocytes and nonmyocytes separately, we showed that TGF-β–Smad2 signaling is an endogenous negative regulator of cardiac cell proliferation. The increase in proliferative capacity in cardiac myocytes was associated with an upregulation of the expres-

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009



Figure 8. Schematic model of a stage-specific role of endogenous Smad2 activation in cardiomyogenesis of ES cells.

sion of several cell cycle regulators, which have been shown to be targets of TGF-β signaling, such as N- and c-myc, cyclin A2, cdc25A, and p57^{KIP2}. Transgenic expression of c-myc or cyclin A2 in the heart leads to enhanced hyperplastic growth of cardiac myocytes.[28] Mice deficient in N-myc show a hypocellular myocardium.[30] p57^{KIP2} is first detectable in the developing heart at embryonic day (E)10.5 among multiple cell cycle regulators,[31] and elevated expression of p57^{KIP2} is associated with a dramatic reduction in proliferative activity in cardiac myocytes in BMP-10–null mice.[32] Transgenic expression of a constitutive active mutant of ALK5 in mice hearts causes hypoplastic hearts in addition to arresting cardiac looping morphogenesis.[28] These results indicated that endogenous TGF-β suppressed the proliferation of cardiac myocytes through the control of cell cycle regulators, although the effects might not be exclusive to cardiac myocytes, as the nonmyocyte population contained various types of cells. Furthermore, inhibition of TGF-β function led to enhanced cardiac differentiation of nonmyocytes, suggesting that inhibition of TGF-β-Smad2 signaling directed the cells to differentiate into cardiac myocytes. However, as spontaneous differentiation from nonmyocytes to cardiac myocytes was observed in control cells, it could not be excluded that TGF-β–Smad2 inhibition modulated the proliferation of spontaneously differentiated cardiac myocytes, leading to augmented cardiac differentiation.

Our study demonstrated that ES cell differentiation exhibited a unique bimodal activation of Smad2 pathway, in which Nodal/Cripto and TGF-β/activin were responsible for the early and late activation, respectively (Figure 8). Furthermore, the early activation was indispensable for the mesodermal and endodermal induction and the subsequent cardiac differentiation, and the late activation, especially mediated by TGF-β, was inhibitory to cardiomyogenesis through attenuating the proliferation and differentiation of cardiac myocytes. Thus, endogenous TGF-β/Nodal/activin–Smad2/3 signaling has temporally distinct, stage-specific roles in cardiomyogenesis in ES cells. These findings revealed the novel roles of Smad2 signaling in cardiac differentiation of ES cells and may contribute to the efficient production of cardiac myocytes from ES cells for various applications.

Acknowledgments

We thank A. Kosugi, M. Nishikawa, and M. Kuramoto for expert technical assistance and Dr Rosa Serra for kindly providing an adenovirus expressing Smad2 DN.

Sources of Funding

This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan and grants-in-aid from the Ministry of Health, Labor, and Welfare of Japan.

Disclosures

None.

References

1. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. *Circ Res*. 2002;91:189–201.
2. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. *Cell*. 2003;113:685–700.
3. Feng XH, Derynck R. Specificity and versatility in TGF-β signaling through Smads. *Annu Rev Cell Dev Biol*. 2005;21:659–693.
4. Schultheiss TM, Burch JB, Lassar AB. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. *Genes Dev*. 1997;11:451–462.
5. Sakabe M, Matsui H, Sakata H, Ando K, Yamagishi T, Nakajima Y. Understanding heart development and congenital heart defects through developmental biology: a segmental approach. *Congenit Anom*. 2005;45:107–118.
6. Monzen K, Shiojima I, Hiroi Y, Kudoh S, Oka T, Takimoto E, Hayashi D, Hosoda T, Habara-Ohkubo A, Nakaoka T, Fujita T, Yazaki Y, Komuro I. Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen-activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. *Mol Cell Biol*. 1999;19:7096–7105.
7. Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR, Lee RT. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. *Circulation*. 2003;107:1912–1916.
8. Alvarez J, Serra R. Unique and redundant roles of Smad3 in TGF-β-mediated regulation of long bone development in organ culture. *Dev Dyn*. 2004;230:685–699.
9. Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N, Takeshita A, Shimizu K, Ohashi H. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. *Hum Gene Ther*. 2000;11:33–42.
10. Hakuno D, Takahashi T, Lammerding J, Lee RT. Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells. *J Biol Chem*. 2005;280:39534–39544.
11. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Mol Pharmacol*. 2002;62:65–74.
12. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. *Nature*. 1998;393:786–790.
13. Song J, Oh SP, Schrewe H, Nomura M, Lei H, Okano M, Gridley T, Li E. The type II activin receptors are essential for egg cylinder growth, gastrulation, and rostral head development in mice. *Dev Biol*. 1999;213:157–169.
14. Dunn NR, Vincent SD, Oxburgh L, Robertson EJ, Bikoff EK. Combinatorial activities of Smad2 and Smad3 regulate mesoderm formation and patterning in the mouse embryo. *Development*. 2004;131:1717–1728.
15. Parisi S, D'Andrea D, Lago CT, Adamson ED, Persico MG, Minchiotti G. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells. *J Cell Biol*. 2003;163:303–314.
16. Vallier L, Alexander M, Pedersen RA. Activin/nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. *J Cell Sci*. 2005;118:4495–4509.
17. Vallier L, Reynolds D, Pedersen RA. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. *Dev Biol*. 2004;275:403–421.
18. Azhar M, Schultz Jel J, Grupp I, Dorn GW 2nd, Meneton P, Molin DG, Gittenberger-de Groot AC, Doetschman T. Transforming growth factor beta in cardiovascular development and function. *Cytokine Growth Factor Rev*. 2003;14:391–407.

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

19. Behfar A, Zingman LV, Hodgson DM, Rauzier JM, Kane GC, Terzic A, Puceat M. Stem cell differentiation requires a paracrine pathway in the heart. *FASEB J*. 2002;16:1558–1566.
20. Singla DK, Sun B. Transforming growth factor-β2 enhances differentiation of cardiac myocytes from embryonic stem cells. *Biochem Biophys Res Commun*. 2005;332:135–141.
21. Schuldiner M, Yanuka O, Itskovitz-Eldor J, Melton DA, Benvenisty N. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. *Proc Natl Acad Sci U S A*. 2000;97:11307–11312.
22. Chow JF, Lee KF, Chan ST, Yeung WS. Quantification of transforming growth factor β1 (TGFβ1) mRNA expression in mouse preimplantation embryos and determination of TGFβ receptor (type I and type II) expression in mouse embryos and reproductive tract. *Mol Hum Reprod*. 2001;7:1047–1056.
23. Yamanaka Y, Ralston A, Stephenson RO, Rossant J. Cell and molecular regulation of the mouse blastocyst. *Dev Dyn*. 2006;235:2301–2314.
24. Nagy A, Vintersten K. Murine embryonic stem cells. *Methods Enzymol*. 2006;418:3–21.
25. Stennard FA, Harvey RP. T-box transcription factors and their roles in regulatory hierarchies in the developing heart. *Development*. 2005;132:4897–4910.
26. Goetz SC, Brown DD, Conlon FL. TBX5 is required for embryonic cardiac cell cycle progression. *Development*. 2006;133:2575–2584.
27. Hatcher CJ, Kim MS, Mah CS, Goldstein MM, Wong B, Mikawa T, Basson CT. TBX5 transcription factor regulates cell proliferation during cardiogenesis. *Dev Biol*. 2001;230:177–188.
28. Ahuja P, Sdek P, Maclellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. *Physiol Rev*. 2007;87:521–544.
29. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. *J Biol Chem*. 1998;273:10261–10269.
30. Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, Robertson EJ, Alt FW. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. *Genes Dev*. 1992;6:2248–2257.
31. Kochilas LK, Li J, Jin F, Buck CA, Epstein JA. $p57^{Kip2}$ expression is enhanced during mid-cardiac murine development and is restricted to trabecular myocardium. *Pediatr Res*. 1999;45:635–642.
32. Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien KR, Conway SJ, Yoder MC, Haneline LS, Franco D, Shou W. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. *Development*. 2004;131:2219–2231.

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

Materials and methods

ES Cell Culture and Differentiation

CGR8 mouse ES cells and ES cells stably transfected with α-myosin heavy chain (MHC) promoter-driven EGFP were cultured as described previously[1], except substituting 15% Knockout Serum Replacement (Invitrogen) for fetal bovine serum. Differentiation was induced by forming embryoid bodies (EB) in the hanging drop suspension culture.[1,2] SB-431542 was purchased from Tocris. Neutralizing monoclonal antibodies against Activin A and TGF-βs were obtained from R&D systems.

RT-PCR and Immunoblot Analysis

Gene expression was analyzed by semi-quantitative PCR or kinetic real time PCR.[1-3] For sorted cells, total RNA was exacted using RNeasy Micro kit (Qiagen) and analyzed with SuperScript III Platinum SYBR Green One-Step qPCR kit (Invitrogen). The primer sequences and TaqMan Gene Expression Assays used in this study are available upon request. Immunoblot analysis was performed[1,3] with a primary antibody against Smad1, Smad2/3, TGF-β receptor type II (Millipore), phospho-Smad1/5/8, phospho-Smad2 (Cell Signaling Technology), sarcomeric myosin (MF20;

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

Developmental Studies Hybridoma Bank), α-actinin (EA-53; Sigma) or GAPDH (Chemicon). For TGF-β receptor type II, the conditioned medium from the cells infected with an adenovirus was analyzed. Densitomeric analysis was performed using ImageJ software.

Replication-defective Recombinant Adenoviruses

Adenoviral vectors expressing a soluble type II TGF-β receptor (sTGF-βIIR), dominant negative mutant of Smad2 or β-galactosidase (LacZ) were prepared as described previously.[4-6] Adenoviral titer was determined by scoring the cytopathic effect in 293T cells using the tissue culture infectious dose 50 method. Cells were infected with adenoviruses at an MOI of 100 in day 0 and at an MOI of 500 in day 5, which produced an almost 100% rate of infection.

Flow Cytometric Analysis and Cell Sorting

α-MHC-EGFP ES cells were dissociated with collagenase type 2 (Worthington), washed, and then immediately analyzed with a FACSCalibur Flow Cytometer using CellQuest acquisition and analysis software (BD Biosciences).[7] Total events of 20,000

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

were analyzed in each sample. Cell sorting was performed with FACSAria cell sorter using FACSDiva software (BD Biosciences).

Immunostaining

Cells were stained with the primary antibody against sarcomeric α-actinin or βIII-tubulin (Sigma), followed by Alexa Fluor 555-conjugated rabbit anti-mouse IgG secondary antibody (Invitrogen). Nuclear staining was performed with DAPI. For phospho-histone H3 staining, sorted cells were centrifuged onto polylysine slides (Cytospin, Shandon), and stained with anti-phospho-histone H3 antibody (Millipore) and Alexa Fluor 568-conjugated goat anti-rabbit IgG secondary antibody (Invitrogen).

BrdU Incorporation Assay

Cells were labeled with 10 μmol/L BrdU for 2 hours at day 8. After being washed, cells were dissociated with collagenase type 2, sorted, centrifuged onto polylysine slides, fixed in 100% ethanol, and stained with anti-BrdU antibody (Roche) and Alexa Fluor 555-conjugated rabbit anti-mouse IgG.

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

Statistical Analysis

All experiments were performed at least 3 times, and data were expressed as mean ± standard deviation, and analyzed by Student's *t* test or One-way ANOVA with post hoc analysis. A value of $P<0.05$ was considered statistically significant.

References

1. Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR, Lee RT. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. *Circulation.* 2003;107:1912-1916.

2. Hakuno D, Takahashi T, Lammerding J, Lee RT. Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells. *J Biol Chem.* 2005;280:39534-39544.

3. Nakajima N, Takahashi T, Kitamura R, Isodono K, Asada S, Ueyama T, Matsubara H, Oh H. MicroRNA-1 facilitates skeletal myogenic differentiation without affecting osteoblastic and adipogenic differentiation. *Biochem Biophys Res Commun.* 2006;350:1006-1012.

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

4. Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N, Takeshita A, Shimizu K, Ohashi H. A soluble Transforming Growth Factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. *Hum Gene Ther.* 2000;11:33-42.

5. Alvarez J, Serra R. Unique and redundant roles of Smad3 in TGF-β-mediated regulation of long bone development in organ culture. *Dev Dyn.* 2004;230:685-699.

6. Ueyama T, Kasahara H, Ishiwata T, Nie Q, Izumo S. Myocardin expression is regulated by Nkx2.5, and its function is required for cardiomyogenesis. *Mol Cell Biol.* 2003;23:9222-9232.

7. Tateishi K, Ashihara E, Honsho S, Takehara N, Nomura T, Takahashi T, Ueyama T, Yamagishi M, Yaku H, Matsubara H, Oh H. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3β signaling. *Biochem Biophys Res Commun.* 2007;352:635-641.

Downloaded from circres.ahajournals.org at SWETS SUBS SERV-#30115043 on March 15, 2009

ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

Biochemical and Biophysical Research Communications 359 (2007) 341–347

BBRC

www.elsevier.com/locate/ybbrc

Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/Akt pathway

Takehiro Ogata [a], Tomomi Ueyama [a,*], Tetsuya Nomura [a,b], Satoshi Asada [a,b], Masashi Tagawa [a,b], Tomoyuki Nakamura [c], Tomosaburo Takahashi [a,b], Hiroaki Matsubara [a,b], Hidemasa Oh [a,*]

[a] *Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan*
[b] *Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto 602-8566, Japan*
[c] *Department of Pharmacology, Kansai Medical University, Moriguchi, Osaka 570-8507, Japan*

Received 11 May 2007
Available online 24 May 2007

Abstract

We have reported that skeletal myosphere-derived progenitor cells (MDPCs) can differentiate into vascular cells, and that MDPC transplantation into cardiomyopathic hearts improves cardiac function. However, the autocrine/paracrine molecules and underlying mechanisms responsible for MDPC growth have not yet been determined. To explore the molecules enhancing the proliferation of MDPCs, we performed serial analysis of gene expression and signal sequence trap methods using RNA isolated from MDPCs. We identified osteopontin (OPN), a secretory molecule, as one of most abundant molecules expressed in MDPCs. OPN provided a proliferative effect for MDPCs. MDPCs treated with OPN showed Akt activation, and inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway repressed the proliferative effect of OPN. Furthermore, OPN-pretreated MDPCs maintained their differentiation potential into endothelial and vascular smooth muscle cells. These findings indicate an important role of OPN as an autocrine/paracrine molecule in regulating the proliferative growth of muscle-derived angiogenic progenitor cells via the PI3K/Akt pathway.
© 2007 Elsevier Inc. All rights reserved.

Keywords: Osteopontin; Skeletal muscle; Progenitor cells; Proliferation; Differentiation

Studies carried out in the past few years have shown adult skeletal muscle tissue contains stem cells able to differentiate into several lineages [1–5]. We have reported the isolation of multipotent progenitor cells from adult skeletal muscle tissue [6] on the basis of their proliferative potential to form floating-spheres (termed myospheres) [5]. Myosphere-derived progenitor cells (MDPCs) have phenotypic characteristics resembling mesenchymal stem cells and differentiate into endothelial and smooth muscle cells. When MDPCs were grafted into δ-sarcoglycan knockdown hearts that served as a model of cardiomyopathy, neoangiogenesis was enhanced and cardiac function was improved. Since skeletal muscle is an easily accessible tissue source, MDPCs have the potential for clinical application to treat patients with heart failure. For efficient autologous transplantation as a regenerative therapy, sufficient numbers of expanded MDPCs from small tissue samples will be required. However, little is known about the molecules and mechanisms controlling MDPC self-renewal.

In adult neural stem cells (NSCs), a glycosylated form of cystein C [7] and insulin-like growth factor-1 [8] are essential autocrine/paracrine molecules identified as cofactors of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), respectively. Stem cell-derived neural

* Corresponding authors. Fax: +81 75 751 4741 (T. Ueyama).
E-mail addresses: tueyama@kuhp.kyoto-u.ac.jp (T. Ueyama), hidemasa@kuhp.kyoto-u.ac.jp (H. Oh).

0006-291X/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2007.05.104

stem/progenitor cell supporting factor has been also identified as an autocrine/paracrine factor that facilitates the proliferative growth of adult NSCs [9]. Therefore, we anticipated that MDPCs could produce autocrine/paracrine factors that regulate their own proliferative growth. In the present study, we identified osteopontin (OPN, also referred to as secreted phosphoprotein 1), a secreted molecule that promotes the proliferative growth of MDPCs, and clarified the role of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway in MDPCs treated with OPN.

Materials and methods

MDPC isolation. MDPC isolation was performed as previously described [6]. Briefly, the primary hindlimb muscle cells were isolated from 8-week-old C57BL/6J mice (Shimizu Laboratories Supplies) using 470 U/ml collagenase type II (Worthington) for digestion. Cells were suspended in the isolation medium, which was DMEM/F12 (Invitrogen) supplemented with B27 (Invitrogen), 20 ng/ml EGF (SIGMA), and 40 ng/ml recombinant bFGF (Promega). Cell suspensions were then cultured onto a non-coated dish at 20 cells/μl density over 7 days to generate myospheres.

MDPC expansion and differentiation. Myospheres were picked and transferred into fibronectin-coated culture plates in an expansion medium composed of Advanced DMEM/F12 (Invitrogen), 200 μM L-glutamine (SIGMA), 2% fetal bovine serum (FBS), 20 ng/ml EGF, 10 ng/ml bFGF, and 10 ng/ml LIF (CHEMICON) to obtain MDPCs. Differentiation medium containing DMEM/F12 and 10% FBS supplemented with 10 ng/ml vascular endothelial growth factor (VEGF; R&D Systems) or 50 ng/ml platelet-derived growth factor-BB (PDGF; R&D Systems) was used to induce endothelial or smooth muscle cell differentiation, respectively.

Serial analysis of gene expression (SAGE). The SAGE libraries were constructed essentially following the I-SAGE long kit protocol (Invitrogen) using total RNA extracted from MDPCs. The double-stranded cDNA was digested with NlaIII and the restriction enzyme was replaced by MmeI after linker ligation. Ditags produced from 400 PCRs were isolated, cleaved with NlaIII, and cloned into pZErO. All sequence files were processed using the SAGE2000 ver. 4.5 software. The extracted tags were further processed to determine the identity of associated genes through several stringent filters using the CGAP website (http://cgap.nci.nih.gov/SAGE).

Signal sequence trap (SST). SST was performed as previously described [10,11]. Briefly, a library was constructed in the retrovirus vector pMX-SST employing cDNA derived from mRNA isolated from MDPCs. The interleukin-3 (IL-3)-dependent pro-B cell line Ba/F3 was infected with retrovirus, followed by seeding onto 96-multiwell plates in the absence of IL-3. Genomic DNAs extracted from IL-3-independent Ba/F3 clones were subjected to PCR to recover the integrated cDNAs using primers specific for the cloning vector. After electrophoresis of the PCR products, DNA was recovered and subjected to sequencing.

Immunofluorescent microscopy. Specimens were fixed in 4% paraformaldehyde and stained with rabbit monoclonal anti-OPN antibody (IBL, Fujioka, Japan), rat monoclonal anti-CD31 antibody (BD Biosciences), and mouse monoclonal anti-smMHC antibody (DAKO). Secondary antibodies were conjugated with Alexa Flour 555, and nuclei were visualized using 4′,6-diamino-2-phenylindole (DAPI; Invitrogen).

RNA extraction and quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR). Total RNA was extracted from MDPCs using the RNeasy mini kit (QIAGEN) and cDNA was synthesized by the SuperScript III kit (Invitrogen). Synthesized cDNA was analyzed by kinetic real-time PCR using the ABI Prism 7700 Sequence Detector system (Applied Biosystems) with SYBR Green Real-time PCR Master Mix (TOYOBO, Osaka). Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalization, and the comparative threshold (C_T) method was used to assess the relative abundance of the targets. Primers used were as follows: OPN-f, GCAGACACTTTCACTCCAATCG; OPN-r, GCCCTTTCCGTTGTTGTCCTG; GAPDH-f, TTGTGATGGGTGTGAACCACGAGA; GAPDH-r, CATGAGCCCTTCCACAATGCCAAA.

MDPC proliferation assay. To test the proliferative effect of OPN or growth factor on MDPCs, recombinant OPN (R&D Systems), LIF, EGF or bFGF was added to the culture medium. Seventy-two hours after treatment, cell proliferation and/or viability effects were estimated using Cell Proliferation Reagent WST-1 (Roche Applied Science), which was added to the culture medium and measured the number of viable cells. Twenty-four hours after treatment, cell proliferation was also estimated by the measurement of BrdU incorporation into newly synthesized cellular DNA using Cell Proliferation ELISA, BrdU (colorimetric) (Roche Applied Science). To estimate the involvement of the PI3K/Akt pathway, MDPCs were pretreated with 1.0 μM LY294002 (CALBIOCHEM) or 5.0 μM Akt inhibitor (CALBIOCHEM) for 30 min.

Western blotting. Cell lysates were extracted with a lysis buffer containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM PMSF, 1× protease inhibitor cocktail (Pierce), 1 mM Na_3VO_4, and 1 mM NaF. Cell lysates were electrophoresed on 10% SDS–polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore). Transferred membranes were incubated with primary antibodies against phospho-Akt (S473) and Akt (Cell Signaling). Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (GE Healthcare) was used as a secondary antibody.

Statistical analysis. All experiments were performed at least three times. Data were expressed as means ± standard error and analyzed by one-way ANOVA with post hoc analysis. A value of $P < 0.05$ was considered significant.

Results

Identification of osteopontin

To explore the potential molecules regulating MDPC proliferation, we performed SAGE and SST using RNA isolated from MDPCs. SAGE provides a comprehensive approach for elucidation of quantitative gene expression patterns that does not depend on prior availability of transcript information [12], and SST is an efficient strategy to identify secreted and cell-surface molecules [11]. By using the two distinct methods, we identified OPN, a secretory molecule, as one of the most abundant molecules expressed in MDPCs. To confirm OPN expression in MDPCs, we performed immunostaining using an anti-OPN antibody. As shown in Fig. 1A, OPN protein was readily detected in myospheres and individual MDPCs.

When MDPCs were isolated and expanded, we used an isolation medium and an expansion medium, respectively. Both media contain bFGF and EGF, while LIF was also used in the expansion medium. Since bFGF has been reported to increase OPN mRNA expression in rat osteosarcoma cells [13], we speculated that the growth factors used might affect OPN expression during the isolation and expansion of MDPCs. To examine this possibility, quantitative RT-PCR for OPN mRNA was performed using total RNA isolated from MDPCs treated with or without the growth factors. Among the growth factors used in the present study, bFGF enhanced OPN mRNA expression in MDPCs (Fig. 1B), whereas EGF and LIF did not. The addition of exogenous OPN did not alter



Fig. 1. OPN expression in MDPCs. (A) OPN expression in spheroid or attached MDPCs was examined by immunostaining using an anti-OPN antibody. Bar indicates 200 μm. (B) MDPCs were treated with or without the growth factors for 12 h. OPN mRNA expression in MDPCs was assessed by real-time RT-PCR. Concentrations of LIF, EGF, and bFGF were 10, 20, and 10 ng/ml, respectively. (C) Cell proliferation activity was assessed using the WST-1 and BrdU ELISA assay systems. MDPCs were treated with or without the growth factors. Values are means ± SEM. $^{**}P < 0.01$ vs control.

endogenous OPN mRNA expression in MDPCs, indicating that OPN has no feedback regulation on its own expression. Furthermore, to investigate which of these growth factors contributes to MDPC proliferation, we measured cell proliferation activity by using WST-1 and BrdU ELISA assays (Fig. 1C). Significant increases in the number of viable MDPCs estimated by the WST-1 assay were seen in EGF- and bFGF-treated MDPCs, and increased DNA synthesis measured by the BrdU ELISA assay was detected in bFGF-treated MDPCs, suggesting that both EGF and bFGF have proliferative effects for MDPCs. In contrast, LIF had no obvious proliferative effect on MDPCs.

OPN has a proliferative effect for MDPCs

We then examined the role of OPN on MDPC proliferation. When the recombinant OPN protein was added to the culture medium containing 2% FBS and growth factors (bFGF, EGF, and LIF) to mimic the culture condition for MDPCs expansion, slight but significant increases in the numbers of viable MDPCs and DNA synthesis were observed in 5.0 μg/ml OPN-treated MDPCs as estimated by WST-1 assay and BrdU ELISA assay, respectively (Fig. 2A). Even if FBS was removed from the above medium mimicking the culture condition for MDPC isolation, the addition of OPN at a concentration of 5.0 μg/ml also induced a significant increase in MDPC proliferation (Fig. 2B). These findings suggest that OPN cooperates with bFGF, EGF, and LIF to induce MDPC proliferation during isolation and expansion of MDPCs.

The findings showed in Fig. 1B suggest that OPN is secreted into the culture medium from MDPCs treated with the growth factors. This may have caused additional OPN treatment to show only a slight effect on growth factors-treated MDPC proliferation as shown is Fig. 2A and B. Furthermore, the results obtained above did not reveal whether OPN alone in the absence of the growth factors could have an effect on MDPC proliferation. Therefore, to clarify the proliferative effect of OPN alone, the recombinant OPN protein was added to the culture medium without FBS and the growth factors, and then cell proliferation activity was assessed. As shown in Fig. 2C, OPN significantly increased MDPC proliferation as assessed by the cell number (right panel) and DNA synthesis (left panel) in a dose dependent manner.

The proliferation of MDPCs induced by OPN depends on the PI3K/Akt pathway

OPN has been reported to activate various kinases such as PI3K, nuclear factor inducing kinase, protein kinase C,



Fig. 2. Enhancement of proliferation effect on MDPCs by OPN. Cell proliferation activity was assessed by use of the WST-1 and BrdU ELISA assay systems. (A) MDPCs were treated with or without 5.0 μg/ml OPN in the culture medium containing 2% FBS and GFs. (B) MDPCs were treated with or without 5.0 μg/ml OPN in the culture medium containing GFs. (C) MDPCs were treated with indicated concentrations of OPN in the culture medium without FBS and GFs. Values are means ± SEM. GFs, growth factor mix (10 ng/ml LIF, 20 ng/ml EGF, and 10 ng/ml bFGF). $^{*}P<0.05$, $^{**}P<0.01$ vs control.

and MAP kinases [14]. Since we have shown that the proliferation of cardiac stem cells (CSCs) is dependent on the Akt pathway [15], we investigated whether OPN induces Akt activation in MDPCs. As shown in Fig. 3A, OPN-induced Akt phosphorylation was detected within 15 min after the addition of OPN, reached a maximum at around 30 min, and then declined. Since Akt is one of downstream target molecules of PI3K, we then examined whether OPN-induced activation of the PI3K/Akt pathway regulates MDPC proliferation. To define the role of the PI3K/Akt pathway, we used inhibitors for PI3K and Akt. OPN-induced Akt phosphorylation was inhibited by 1.0 μM of LY294002, a PI3K inhibitor, and 5.0 μM of Akt inhibitor in MDPCs (data not shown). Therefore, we treated MDPCs with 1.0 μM LY294002 or 5.0 μM Akt inhibitor, followed by the addition of OPN, and then measured cell proliferation activity. As shown in Fig. 3B, pretreatment with LY294002 inhibited OPN-induced MDPC proliferation as assessed by WST-1 and BrdU ELISA assays. Akt inhibition also reduced OPN-induced MDPC proliferation as assessed by WST-1 and BrdU ELISA assays (Fig. 3C). These results indicate that OPN-induced MDPC proliferation depends on the PI3K/Akt pathway.

OPN-treated MDPCs can differentiate into endothelial and smooth muscle cells

Finally, we examined the potential of MDPCs treated with OPN to differentiate into vascular cells. MDPCs that had been treated with 1.0 μg/ml of OPN for 4 days were induced into endothelial and smooth muscle cell differentiation using VEGF and PDGF, respectively. Immunostaining using an anti-CD31 antibody showed that CD31 positive cells appeared by 14 days after treatment with VEGF (Fig. 4, upper panel). When MDPCs treated by OPN were cultured in the differentiation medium containing PDGF for 14 days, smMHC positive cells were observed (Fig. 4, lower panel). These results indicate that OPN-treated MDPCs retained their replicative growth capacity and could maintain the commitment to differentiate into at least two different vascular lineages: endothelial and smooth muscle cells.

Discussion

OPN has been known to be involved in many physiological and pathological processes including cell adhesion, angiogenesis, apoptosis, inflammatory responses and tumor metastasis [16]. Here, we identify OPN as a myosphere-derived secretory molecule, and provide a novel role of OPN in regulating the proliferative growth of MDPCs through the PI3K/Akt signaling pathway.

bFGF and EGF have been revealed to affect the rates of proliferation for neural stem and progenitor cells [17]. Studies from single cell cultures demonstrated that EGF and bFGF are mitogens for neurospheres [18,19]. Both bFGF and EGF were also used for the isolation of CSCs as a cardiosphere from the heart [20]. Muscle-derived stem cells were isolated as a myosphere from skeletal muscle by Sarig et al. using bFGF and LIF [5]. Similarly, we have shown that MDPCs as well as CSCs can be isolated as a sphere and expanded using bFGF, EGF, and LIF [6,15]. Regarding the proliferation of MDPCs, we demonstrated here that proliferative effects were dependent on bFGF and EGF but not LIF, and that the effect of bFGF was greater than that of EGF. The previous report by Sarig et al. showed that LIF increased the proportion of Sca-1 expressing muscle-derived stem cells from 15% to 80% [5]. Since we have used MDPCs that highly express Sca-1



Fig. 3. OPN stimulates proliferation of MDPCs through the PI3K/Akt signaling pathway. (A) MDPCs were treated with 5.0 μg/ml OPN for various time periods. Cell extracts were subjected to Western blotting (left panel) using an anti-phospho-specific Akt antibody (p-Akt, upper panel) or an anti-Akt antibody (Akt, lower panel). Right graph shows the time course of relative phosphorylation of Akt during OPN treatment. The experiment shown represents one of three independent trials that gave nearly identical results. (B,C) Cell proliferation activity was assessed by use of the WST-1 and BrdU ELISA assay systems. Cell proliferation and DNA synthesis of MDPCs induced by OPN were inhibited by pretreatment with LY294004, a PI3K inhibitor (B), or Akt inhibitor (C). Values are means ± SEM. LY, LY294002; Akt-I, Akt inhibitor. $^{**}P < 0.01$ vs control; $^{\dagger}P < 0.05$, $^{\dagger\dagger}P < 0.01$ vs 5.0 μg/ml OPN.

(FACS analysis, 84.0 ± 2.6%) [6], the discrepant result between our study and Sarig et al. [5] regarding the effect of LIF might be due to the population of Sca-1 expressing cells. We also found that OPN expression was enhanced by bFGF but not EGF and LIF in MDPCs, and that OPN promotes MDPC proliferation. These findings suggest that OPN contributes to bFGF-induced MDPC proliferation.

OPN has a protease-hypersensitive site that separates the integrin- and CD44-binding domains and exerts its effects by interacting with various integrins and CD44 receptors [14]. We have shown that CD29 (also known as β1 integrin) and CD44 are expressed on MDPCs [6]. OPN has been shown to activate the PI3K/Akt signaling pathway through αvβ3 integrin- and CD44-mediated pathways [21,22]. Furthermore, CD44 has been demonstrated to cooperate with β1 integrin to bind OPN [23]. Therefore, our findings suggest that CD44 and β1 integrin may mediate OPN-induced activation of the PI3K/Akt signaling pathway and allow the proliferative growth of MDPCs.

Extensive research using OPN-knockdown by siRNA and OPN-null mutant mice has demonstrated that OPN promotes the growth or survival of tumor cells [14,24–27]. Similar to the effect of OPN on tumor cells, we showed a proliferative effect of OPN on MDPCs in the present study. We also demonstrated that OPN-treated MDPCs retained the ability to differentiate into vascular cells. OPN expression has been revealed to be up-regulated in regenerating skeletal muscle after injury [28]. A study using OPN-null mutant mice also demonstrated that OPN was required for efficient angiogenesis in ectopically implanted bone discs in skeletal muscle [29]. Taken together with our findings, these data suggest that OPN is involved in the proliferation of MDPCs and angiogenesis by MDPCs in skeletal muscle. However, in primitive hematopoietic stem cells (HSCs) OPN has been reported to be a critical component of the HSC niche within the bone marrow microenvironment, and to work as a negative regulator of HSC proliferation [30,31]. The reason why OPN has opposite



Fig. 4. MDPCs maintain a capacity of differentiation into cardiovascular lineages after treatment with OPN. Immunostaining was performed using an anti-CD31 antibody or an anti-smMHC antibody. MDPCs treated with OPN were differentiated into CD31 positive endothelial (red) or smMHC positive smooth muscle (red) cells by VEGF or PDGF, respectively. Nuclei were stained by DAPI (blue). Bar indicates 50 μm.

effects on HSC and MDPC proliferation is unclear. HSCs have been shown to express several integrins and various isoforms of CD44 [32]. Except for the expression of CD44 and β1 integrin on MDPCs [6], it remains to be determined whether isoforms of CD44 and other integrins are expressed on MDPCs. Since the different effects that OPN elicits can be attributed to its multiple receptors, binding sites, and various forms [33], the expression pattern of integrins and CD44 isoforms in MDPCs may differ from that in HSCs.

In conclusion, we identified OPN as a secreted molecule in MDPCs by using SAGE and SST. Recombinant OPN had a proliferative effect on MDPCs with or without various growth factors, and PI3K/Akt signaling was involved in the effect. Furthermore, MDPCs treated with OPN had an enhanced proliferative potential and maintained their potency to differentiate into vascular lineages. Thus, OPN may be one of the candidate autocrine/paracrine molecules that could be applied in a therapeutic intervention using MDPCs to treat patients with vascular diseases.

Acknowledgments

We are grateful to Ms. A. Kosugi, Ms. M. Nishikawa, and Mr. M. Kuramoto for their skillful technical assistance. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by Grants-in-Aid from the Ministry of Health, Labor, and Welfare of Japan, Japan Association for the Advancement of Medical Equipment, Takeda Science Foundation, Novartis Research Award on Molecular and Cellular Cardiology, Kanae Foundation for Life & Socio-Medical Science, Suzuken Memorial Foundation, and Mochida Memorial Foundation.

References

[1] Z. Qu-Petersen, B. Deasy, R. Jankowski, M. Ikezawa, J. Cummins, R. Pruchnic, J. Mytinger, B. Cao, C. Gates, A. Wernig, J. Huard, Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration, J. Cell Biol. 157 (2002) 851–864.
[2] H. Oshima, T.R. Payne, K.L. Urish, T. Sakai, Y. Ling, B. Gharaibeh, K. Tobita, B.B. Keller, J.H. Cummins, J. Huard, Differential myocardial infarct repair with muscle stem cells compared to myoblasts, Mol. Ther. 12 (2005) 1130–1141.
[3] T.R. Payne, H. Oshima, T. Sakai, Y. Ling, B. Gharaibeh, J. Cummins, J. Huard, Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells, Gene Ther. 12 (2005) 1264–1274.
[4] T. Tamaki, A. Akatsuka, K. Ando, Y. Nakamura, H. Matsuzawa, T. Hotta, R.R. Roy, V.R. Edgerton, Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle, J. Cell Biol. 157 (2002) 571–577.
[5] R. Sarig, Z. Baruchi, O. Fuchs, U. Nudel, D. Yaffe, Regeneration and transdifferentiation potential of muscle-derived stem cells propagated as myospheres, Stem Cells 24 (2006) 1769–1778.
[6] T. Nomura, E. Ashihara, K. Tateishi, S. Asada, T. Ueyama, T. Takahashi, H. Matsubara, H. Oh, Skeletal myosphere-derived progenitor cell transplantation promotes neovascularization in δ-sarcoglycan knockdown cardiomyopathy, Biochem. Biophys. Res. Commun. 352 (2007) 668–674.
[7] P. Taupin, J. Ray, W.H. Fischer, S.T. Suhr, K. Hakansson, A. Grubb, F.H. Gage, FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor, Neuron 28 (2000) 385–397.
[8] Y. Arsenijevic, S. Weiss, B. Schneider, P. Aebischer, Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2, J. Neurosci. 21 (2001) 7194–7202.
[9] H. Toda, M. Tsuji, I. Nakano, K. Kobuke, T. Hayashi, H. Kasahara, J. Takahashi, A. Mizoguchi, T. Houtani, T. Sugimoto, N. Hashimoto, T.D. Palmer, T. Honjo, K. Tashiro, Stem cell-derived neural

stem/progenitor cell supporting factor is an autocrine/paracrine survival factor for adult neural stem/progenitor cells, J. Biol. Chem. 278 (2003) 35491–35500.

[10] T. Nakamura, P. Ruiz-Lozano, V. Lindner, D. Yabe, M. Taniwaki, Y. Furukawa, K. Kobuke, K. Tashiro, Z. Lu, N.L. Andon, R. Schaub, A. Matsumori, S. Sasayama, K.R. Chien, T. Honjo, DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries, J. Biol. Chem. 274 (1999) 22476–22483.

[11] T. Kojima, T. Kitamura, A signal sequence trap based on a constitutively active cytokine receptor, Nat. Biotechnol. 17 (1999) 487–490.

[12] V.E. Velculescu, B. Vogelstein, K.W. Kinzler, Analysing uncharted transcriptomes with SAGE, Trends Genet. 16 (2000) 423–425.

[13] S.B. Rodan, G. Wesolowski, K. Yoon, G.A. Rodan, Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells, J. Biol. Chem. 264 (1989) 19934–19941.

[14] H. Rangaswami, A. Bulbule, G.C. Kundu, Osteopontin: role in cell signaling and cancer progression, Trends Cell Biol. 16 (2006) 79–87.

[15] K. Tateishi, E. Ashihara, S. Honsho, N. Takehara, T. Nomura, T. Takahashi, T. Ueyama, M. Yamagishi, H. Yaku, H. Matsubara, H. Oh, Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3β signaling, Biochem. Biophys. Res. Commun. 352 (2007) 635–641.

[16] D.N. Haylock, S.K. Nilsson, Osteopontin: a bridge between bone and blood, Br. J. Haematol. 134 (2006) 467–474.

[17] S. Temple, A. Alvarez-Buylla, Stem cells in the adult mammalian central nervous system, Curr. Opin. Neurobiol. 9 (1999) 135–141.

[18] A. Gritti, E.A. Parati, L. Cova, P. Frolichsthal, R. Galli, E. Wanke, L. Faravelli, D.J. Morassutti, F. Roisen, D.D. Nickel, A.L. Vescovi, Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor, J. Neurosci. 16 (1996) 1091–1100.

[19] B.A. Reynolds, S. Weiss, Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell, Dev. Biol. 175 (1996) 1–13.

[20] E. Messina, L. De Angelis, G. Frati, S. Morrone, S. Chimenti, F. Fiordaliso, M. Salio, M. Battaglia, M.V. Latronico, M. Coletta, E. Vivarelli, L. Frati, G. Cossu, A. Giacomello, Isolation and expansion of adult cardiac stem cells from human and murine heart, Circ. Res. 95 (2004) 911–921.

[21] Y.H. Lin, H.F. Yang-Yen, The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway, J. Biol. Chem. 276 (2001) 46024–46030.

[22] R. Das, G.H. Mahabeleshwar, G.C. Kundu, Osteopontin stimulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells, J. Biol. Chem. 278 (2003) 28593–28606.

[23] Y.U. Katagiri, J. Sleeman, H. Fujii, P. Herrlich, H. Hotta, K. Tanaka, S. Chikuma, H. Yagita, K. Okumura, M. Murakami, I. Saiki, A.F. Chambers, T. Uede, CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis, Cancer Res. 59 (1999) 219–226.

[24] H.C. Crawford, L.M. Matrisian, L. Liaw, Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo, Cancer Res. 58 (1998) 5206–5215.

[25] Y. Wu, D.T. Denhardt, S.R. Rittling, Osteopontin is required for full expression of the transformed phenotype by the ras oncogene, Br. J. Cancer 83 (2000) 156–163.

[26] S.R. Rittling, A.F. Chambers, Role of osteopontin in tumour progression, Br. J. Cancer 90 (2004) 1877–1881.

[27] D. Denhardt, Osteopontin expression correlates with melanoma invasion, J. Invest. Dermatol. 124 (2005) xvi–xviii.

[28] A. Hirata, S. Masuda, T. Tamura, K. Kai, K. Ojima, A. Fukase, K. Motoyoshi, K. Kamakura, Y. Miyagoe-Suzuki, S. Takeda, Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin, Am. J. Pathol. 163 (2003) 203–215.

[29] Y. Asou, S.R. Rittling, H. Yoshitake, K. Tsuji, K. Shinomiya, A. Nifuji, D.T. Denhardt, M. Noda, Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone, Endocrinology 142 (2001) 1325–1332.

[30] S.K. Nilsson, H.M. Johnston, G.A. Whitty, B. Williams, R.J. Webb, D.T. Denhardt, I. Bertoncello, L.J. Bendall, P.J. Simmons, D.N. Haylock, Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells, Blood 106 (2005) 1232–1239.

[31] S. Stier, Y. Ko, R. Forkert, C. Lutz, T. Neuhaus, E. Grunewald, T. Cheng, D. Dombkowski, L.M. Calvi, S.R. Rittling, D.T. Scadden, Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size, J. Exp. Med. 201 (2005) 1781–1791.

[32] P.J. Simmons, J.P. Levesque, A.C. Zannettino, Adhesion molecules in haemopoiesis, Baillieres Clin. Haematol. 10 (1997) 485–505.

[33] D.T. Denhardt, X. Guo, Osteopontin: a protein with diverse functions, FASEB J. 7 (1993) 1475–1482.

Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration

Kento Tateishi[1,2], Eishi Ashihara[1], Naofumi Takehara[1], Tetsuya Nomura[1,2], Shoken Honsho[2], Takuo Nakagami[2,3], Shigehiro Morikawa[4], Tomosaburo Takahashi[1,2], Tomomi Ueyama[1], Hiroaki Matsubara[1,2,*] and Hidemasa Oh[1,*]

[1]Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan
[2]Department of Cardiovascular Medicine, [3]Departments of Pathology and Cell Regulation, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
[4]Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga 520-2192, Japan
*Authors for correspondence (e-mail: matsubah@koto.kpu-m.ac.jp; hidemasa@kuhp.kyoto-u.ac.jp)

Accepted 25 March 2007
Journal of Cell Science 120, 1791-1800 Published by The Company of Biologists 2007
doi:10.1242/jcs.006122

Summary

Recent studies have shown that cardiac stem cells (CSCs) from the adult mammalian heart can give rise to functional cardiomyocytes; however, the definite surface markers to identify a definitive single entity of CSCs and the molecular mechanisms regulating their growth are so far unknown. Here, we demonstrate a single-cell deposition analysis to isolate individually selected CSCs from adult murine hearts and investigate the signals required for their proliferation and survival. Clonally proliferated CSCs express stem cell antigen-1 (Sca-1) with embryonic stem (ES) cell-like and mesenchymal cell-like characteristics and are associated with telomerase reverse transcriptase (TERT). Using a transgene that expresses a GFP reporter under the control of the TERT promoter, we demonstrated that TERT^{GFP}-positive fractions from the heart were enriched for cells expressing Sca-1. Knockdown of Sca-1 transcripts in CSCs led to retarded ex vivo expansion and apoptosis through Akt inactivation. We also show that ongoing CSC proliferation and survival after direct cell-grafting into ischemic myocardium require Sca-1 to upregulate the secreted paracrine effectors that augment neoangiogenesis and limit cardiac apoptosis. Thus, Sca-1 might be an essential component to promote CSC proliferation and survival to directly facilitate early engraftment, and might indirectly exert the effects on late cardiovascular differentiation after CSC transplantation.

Key words: Cardiac stem cells, Proliferation, Regeneration, Stem cell antigen-1, Survival, Telomerase

Introduction

The adult mammalian heart harbors a population of mitotically competent cardiac stem cells (CSCs) that can be isolated by using FACS to recognize the cells expressing surface antigens KIT and stem cell antigen-1 (Sca-1) or by targeting a reporter gene driven by the promoter for islet-1, a LIM-homeodomain transcription factor (Beltrami et al., 2003; Laugwitz et al., 2005; Matsuura et al., 2004; Moretti et al., 2006; Oh et al., 2003; Pfister et al., 2005). These cells express essential cardiac transcriptional factors but do not express more mature markers of structural genes; however, the exact contribution of cell fusion in the process of adopting cardiac muscle phenotype after cell transfer into ischemic myocardium remains controversial (Beltrami et al., 2003; Oh et al., 2003). Within the adult heart, CSCs often reside in cardiac niches with supporting cells that provide a specialized environment to replenish and maintain a balance of survival, proliferation and self-renewal of CSCs through symmetric or asymmetric division in order to replace the mature cells that are lost during injury or turnover (Urbanek et al., 2006).

The general lack of definitive molecular markers to identify cardiac stem cells raises the fundamental question of whether these cardiac stem cells are derived from a single entity. CSCs in the mammalian heart share several cell-surface markers with hematopoietic and endothelial progenitor cells (Linke et al., 2005; Messina et al., 2004; Urbanek et al., 2003). Although the hierarchies of hematopoietic stem cells have been well characterized, evidence supporting the role of bone marrow-derived *Lin$^-$-Kit$^+$* cells in cardiac-lineage induction has been controversial (Kawada et al., 2004; Murry et al., 2004; Orlic et al., 2001). Recent reports have demonstrated that genetic disruption of *Kit* in mice mainly affects marrow-derived hematopoietic and endothelial cell development for cardiac repair, that could be rescued by bone marrow replacement with wild-type cells, through the failure of progenitor-cell mobilization from marrow and reduced release of cytokines and chemokines that may participate in the cardioprotective paracrine signaling (Ayach et al., 2006; Fazel et al., 2006). These studies do not exclude the possible functional role of KIT in resident CSCs as the principal mediator in the regenerating process during cardiac injury, but suggest that defining CSCs using specific cell-surface markers may not be optimal to address the identity of these cells, as indicated by their partially overlapping expression in human hearts (Urbanek et al., 2005b).

Journal of Cell Science